This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HROWM Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisDividendTrendsBuy This Stock About Harrow Health, Inc. 11.875% Senior Notes due 2027 Stock (NASDAQ:HROWM) Get HROWM alerts:Sign Up Key Stats Today's Range$26.03▼$26.0350-Day Range$25.94▼$26.3552-Week Range$25.80▼$26.95VolumeN/AAverage Volume7,506 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Harrow Health, Inc. is a diversified biopharmaceutical company focused on improving patient access to innovative ophthalmic therapies. Through its wholly owned subsidiary ImprimisRx®, Harrow Health develops, manufactures and distributes proprietary compounded and generic eye drop formulations for treating a range of anterior segment eye diseases. The company’s product portfolio addresses conditions such as glaucoma, ocular pain and inflammation, and dry eye, and it leverages a direct‐to‐physician distribution model alongside select pharmacy and specialty pharmacy partnerships. Since its founding, Harrow Health has expanded beyond traditional compounding to pursue the commercialization of branded pharmaceutical candidates and digital therapeutics. These efforts include licensing agreements for novel small‐molecule ocular drugs and the development of proprietary platforms aimed at improving formulation stability and patient compliance. Harrow Health’s business strategy emphasizes rapid commercialization of off‐patent ophthalmic formulations while building a pipeline of differentiated products for long‐term growth. Headquartered in Tampa, Florida, Harrow Health serves healthcare providers and patients across the United States, with additional international reach through a network of third-party distributors. The company’s leadership team combines experience in pharmaceutical development, regulatory affairs and specialty pharmacy operations, under the guidance of Chief Executive Officer Anthony Johnson. In April 2022, Harrow Health issued its 11.875% Senior Notes due 2027 (NASDAQ: HROWM) to support ongoing research and development, marketing initiatives and potential strategic acquisitions within the ophthalmology sector.AI Generated. May Contain Errors. Read More Receive HROWM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow Health, Inc. 11.875% Senior Notes due 2027 and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HROWM Stock News HeadlinesHROWM | Harrow Inc. 11.875% Sr. Notes due 2027 Stock Overview (U.S ...September 5, 2025 | barrons.comHarrow Baby Bonds Yield ReviewAugust 22, 2025 | seekingalpha.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.June 20 at 1:00 AM | Chaikin Analytics (Ad)Harrow Inc. 11.875% Sr. Notes due 2027August 28, 2024 | wsj.comHarrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM)May 19, 2024 | finance.yahoo.comSee More Headlines Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (30m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 HROWM's financial health is in the Green zone, according to TradeSmith. HROWM has been in this zone for over 30 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry - Sub-IndustryN/A Current SymbolNASDAQ:HROWM CIK1360214 WebN/A PhoneN/AFaxN/AEmployees125Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:HROWM) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow Health, Inc. 11.875% Senior Notes due 2027 Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow Health, Inc. 11.875% Senior Notes due 2027 With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.